A Whole Blood Assay to assess Individual Patient Responses to Novel Antiviral Therapeutics.
While combination anti-retroviral drugs (cART) can control active HIV-1 virus replication, they are not “curative”. Rather, these drugs are required life-long. Developing new therapeutic strategies that can reduce or clear persistent, underlying sources of virus infection will require novel clinical diagnostic assays and tools. Such tools must comprehensively evaluate virologic, immunologic and safety parameters for individuals who may require personalized therapies.
Jericho Sciences is developing a clinically relevant, diagnostic assay for personalized clinical management of novel therapeutic strategies for controlling HIV-1 infection. Our patented technology assesses patient-specific responses across comparative conditions using multiparametric measures from the full peripheral blood immunologic compartment. Other assays exclude cells other than CD4 T cells. Jericho’s assay more accurately reflects the natural environment of CD4 T cells, the primary target cells of HIV infection.
How the J-Test™ Works
- Draw blood into prefilled collection tubes
- Incubate 2-3 days
- Collect supernatant and cells
- Measure virus production, provirus, cell phenotypes, soluble factors
- Correlate measures
Jericho’s J-Test™ Value Proposition
- Clinically Relevant: Requires small volumes of blood
- Patient-Specific: Internally-referenced
- Short Turnaround Time: Results within 1 week
- Multiparametric: Cellular, viral, and immunologic parameters
- Primary Cells: Immediate responses to virus activation
- Supports Clinical Success: Enables identification of biomarkers
A key remaining question is whether virus-specific immune mechanisms including cytolytic T lymphocytes (CTL) can clear infected cells in ART-treated patients after latency is reversed. …appropriate boosting of this response may be required for the elimination of the latent reservoir.K Deng 2015 (Nature vol. 517,7534 (2015): 381-5)
to inquire how the J-Test™ can better support clinical success of novel antiviral therapeutics